secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059716
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Therapeutics Q3 FY2024 net loss $2.0M ($0.05/sh), cash $6.35M; merger with TuHURA on track
--------------------------------------------------------------------------------

- Net loss of $2.0M (diluted EPS -$0.05) vs $3.3M (-$1.94) in prior-year Q3; narrower loss due to lower R&D.
- Cash and equivalents $6.35M at March 31, 2024, up from $1.54M at June 30, 2023.
- R&D expense fell to $0.59M from $2.01M YoY; G&A rose to $1.49M on merger-related professional fees.
- Merger with TuHURA expected to close in Q3 2024; existing stockholders receive contingent value rights tied to REM-001 milestone.
- REM-001 CMBC study expanded to include pembrolizumab patients; $2.0M NIH SBIR grant covers most study costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/0000950170-24-059716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/ktra-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer